NI201300043A - Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano - Google Patents

Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano

Info

Publication number
NI201300043A
NI201300043A NI201300043A NI201300043A NI201300043A NI 201300043 A NI201300043 A NI 201300043A NI 201300043 A NI201300043 A NI 201300043A NI 201300043 A NI201300043 A NI 201300043A NI 201300043 A NI201300043 A NI 201300043A
Authority
NI
Nicaragua
Prior art keywords
receptor antagonists
cgrp receptor
piperidinone carboxamide
cgrp
carboxamide azaindane
Prior art date
Application number
NI201300043A
Other languages
English (en)
Inventor
M Bell Ian
E Fraley Mark
N Gallicchio Steven
Ginnetti Anthony
J Mitchell Helen
V Paone Daniel
D Staas Donnette
Wang Cheng
Blair Zartman C
E Stevenson Heather
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NI201300043A publication Critical patent/NI201300043A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a derivados de piperadinona carboxamida azaindano que son antagonistas de receptores del CGRP y útiles en el tratamiento o prevención de enfermedades en la que está implicado el CGRP, tales como migraña. La invención también se refiere a composiciones farmacéuticas que comprende estos compuestos y al uso de estos compuestos y composiciones en la prevención o tratamiento de dichas enfermedades en las que está implicado el CGRP.
NI201300043A 2010-11-12 2013-05-10 Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano NI201300043A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41307710P 2010-11-12 2010-11-12
US201061425034P 2010-12-20 2010-12-20

Publications (1)

Publication Number Publication Date
NI201300043A true NI201300043A (es) 2013-07-01

Family

ID=45034191

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201300043A NI201300043A (es) 2010-11-12 2013-05-10 Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano

Country Status (42)

Country Link
US (8) US8912210B2 (es)
EP (2) EP2638042B1 (es)
JP (1) JP5642883B2 (es)
KR (1) KR101537877B1 (es)
CN (1) CN103328478B (es)
AR (1) AR083831A1 (es)
AU (1) AU2011326454B2 (es)
BR (1) BR112013011448B8 (es)
CA (1) CA2817100C (es)
CL (1) CL2013001289A1 (es)
CO (1) CO6801723A2 (es)
CR (1) CR20130214A (es)
CY (2) CY1118362T1 (es)
DK (2) DK2821407T3 (es)
DO (1) DOP2013000103A (es)
EA (1) EA022850B1 (es)
EC (1) ECSP13012676A (es)
ES (2) ES2604827T3 (es)
FI (1) FIC20230034I1 (es)
FR (1) FR23C1039I1 (es)
GT (1) GT201300122A (es)
HK (1) HK1200163A1 (es)
HR (2) HRP20141108T1 (es)
HU (2) HUE031010T2 (es)
IL (1) IL225978A (es)
LT (1) LT2821407T (es)
MA (1) MA34650B1 (es)
ME (2) ME01922B (es)
MX (1) MX2013005246A (es)
MY (1) MY165113A (es)
NI (1) NI201300043A (es)
NL (1) NL301248I2 (es)
NO (1) NO2023040I1 (es)
NZ (1) NZ610468A (es)
PE (1) PE20140240A1 (es)
PL (2) PL2638042T3 (es)
PT (2) PT2638042E (es)
RS (2) RS53610B1 (es)
SG (2) SG190137A1 (es)
SI (2) SI2638042T1 (es)
TW (3) TWI522355B (es)
WO (1) WO2012064910A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI522355B (zh) * 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
EP2685826B1 (en) 2011-03-18 2016-02-03 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US9487523B2 (en) * 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
KR20220108207A (ko) * 2013-09-16 2022-08-02 머크 샤프 앤드 돔 코포레이션 Cgrp 수용체 길항제를 위한 제제
KR102448369B1 (ko) * 2014-02-05 2022-09-28 머크 샤프 앤드 돔 엘엘씨 Cgrp-활성 화합물에 대한 정제 제제
FR3030521B1 (fr) * 2014-12-23 2019-07-26 Galderma Research & Development Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
US20190374520A1 (en) * 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
GB201908430D0 (en) * 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
CN110787163B (zh) * 2019-12-05 2020-06-02 河北医科大学第二医院 一种用于神经保护和促进神经再生的药物组合物及其制剂
EP4188375A4 (en) 2020-07-29 2024-07-24 Allergan Pharmaceuticals Int Ltd TREATMENT OF MIGRAINE
CN112353767A (zh) * 2020-11-16 2021-02-12 海南锦瑞制药有限公司 一种盐酸地尔硫卓和普瑞巴林组合物及其制备方法及其应用
AU2021409718A1 (en) 2020-12-22 2023-07-13 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022185224A1 (en) 2021-03-02 2022-09-09 Mark Hasleton Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
WO2023119327A1 (en) * 2021-12-20 2023-06-29 Msn Laboratories Private Limited, R&D Center Process for the preparation of a pure amorphous form of ubrogepant
TWI847671B (zh) * 2022-04-29 2024-07-01 大陸商熙源安健醫藥（北京）有限公司 哌啶甲醯胺氮雜茚滿類衍生物及其製備方法和用途
WO2024081718A1 (en) 2022-10-11 2024-04-18 Allergan Pharmaceuticals International Limited Cgrp receptor antagonist for the treatment of migraine
WO2024134683A1 (en) * 2022-12-21 2024-06-27 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of intermediate compounds used in the treatment of migraine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
CA2519515A1 (en) 2003-03-14 2004-10-14 Merck & Co., Inc. Benodiazepine spirohydantoin cgrp receptor antagonists
JP4690313B2 (ja) 2003-03-14 2011-06-01 メルク・シャープ・エンド・ドーム・コーポレイション カルボキサミドスピロヒダントインｃｇｒｐ受容体アンタゴニスト
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
CA2579847A1 (en) * 2004-09-13 2006-03-23 Merck & Co., Inc. Bicyclic anilide spirolactam cgrp receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
CN101208303A (zh) * 2005-03-14 2008-06-25 默克公司 Cgrp受体拮抗剂
EP2029575B1 (en) * 2006-05-09 2014-10-22 Merck Sharp & Dohme Corp. Substituted spirocyclic cgrp receptor antagonists
US8993588B2 (en) 2007-06-05 2015-03-31 Merck Sharp & Dohme Corp. Carboxamide heterocyclic CGRP receptor antagonists
CA2705599A1 (en) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh New compounds
US8044043B2 (en) * 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
WO2010139717A1 (de) * 2009-06-05 2010-12-09 Boehringer Ingelheim International Gmbh Neue verbindungen
JP2013542261A (ja) * 2010-11-12 2013-11-21 メルク・シャープ・アンド・ドーム・コーポレーション ピペリジノンカルボキサミドインダンｃｇｒｐ受容体アンタゴニスト
TWI522355B (zh) * 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
EP2654423B1 (en) * 2010-12-22 2016-12-07 Merck Sharp & Dohme Corp. Fused heterocyclic azaindane carboxamide cgrp receptor antagonists
US8895572B2 (en) * 2010-12-22 2014-11-25 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide CGRP receptor antagonists
EP2685826B1 (en) * 2011-03-18 2016-02-03 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
EP2753640B1 (en) * 2011-09-08 2016-03-09 Codexis, Inc. Biocatalysts and methods for the synthesis of substituted lactams
US9487523B2 (en) * 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
AU2013232191B2 (en) * 2012-03-14 2017-03-30 Merck Sharp & Dohme Llc Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts
US9227972B2 (en) * 2012-05-09 2016-01-05 Merck Sharp & Dohme Corp. Aliphatic spirolactam CGRP receptor antagonists
US9296750B2 (en) * 2012-05-09 2016-03-29 Merck Sharp & Dohme Corp. Spirolactam CGRP receptor antagonists
EP2846801B1 (en) * 2012-05-09 2017-04-05 Merck Sharp & Dohme Corp. Pyridine cgrp receptor antagonists
US9174989B2 (en) * 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
KR20220108207A (ko) * 2013-09-16 2022-08-02 머크 샤프 앤드 돔 코포레이션 Cgrp 수용체 길항제를 위한 제제
KR102448369B1 (ko) * 2014-02-05 2022-09-28 머크 샤프 앤드 돔 엘엘씨 Cgrp-활성 화합물에 대한 정제 제제
KR20170003527A (ko) * 2014-02-24 2017-01-09 유리젠 파마슈티컬스, 인코포레이티드 경구 투여용 펜토산 폴리설페이트 염의 조성물
US20180092899A1 (en) * 2016-09-30 2018-04-05 Merck Sharp & Dohme Corp. Method of treating acute migraine with cgrp-active compound

Also Published As

Publication number Publication date
EP2638042A1 (en) 2013-09-18
CY1118362T1 (el) 2017-06-28
AR083831A1 (es) 2013-03-27
AU2011326454B2 (en) 2015-05-21
EP2821407B1 (en) 2016-09-21
MY165113A (en) 2018-02-28
LT2821407T (lt) 2016-12-12
HUS2300037I1 (hu) 2023-11-28
HRP20161641T1 (hr) 2017-01-13
GT201300122A (es) 2015-06-02
ME02552B (me) 2017-02-20
ES2525021T3 (es) 2014-12-16
DK2638042T3 (en) 2015-01-05
US8912210B2 (en) 2014-12-16
ECSP13012676A (es) 2013-08-30
CO6801723A2 (es) 2013-11-29
ES2604827T3 (es) 2017-03-09
IL225978A (en) 2015-11-30
HUE031010T2 (en) 2017-06-28
EP2821407A1 (en) 2015-01-07
NL301248I2 (nl) 2023-11-20
KR101537877B1 (ko) 2015-07-17
PL2821407T3 (pl) 2017-04-28
CY2023022I1 (el) 2024-02-16
SI2638042T1 (sl) 2015-01-30
PT2821407T (pt) 2016-12-06
US8481556B2 (en) 2013-07-09
EA022850B1 (ru) 2016-03-31
AU2011326454A1 (en) 2013-05-23
US20190275024A1 (en) 2019-09-12
EA201390683A1 (ru) 2013-09-30
NZ610468A (en) 2015-06-26
TW201520214A (zh) 2015-06-01
CR20130214A (es) 2013-06-28
US9499545B2 (en) 2016-11-22
CN103328478B (zh) 2015-10-07
JP5642883B2 (ja) 2014-12-17
TWI501968B (zh) 2015-10-01
NO2023040I1 (no) 2023-10-20
PL2638042T3 (pl) 2015-03-31
TW201520213A (zh) 2015-06-01
FIC20230034I1 (fi) 2023-11-10
BR112013011448B1 (pt) 2021-06-01
US20170027925A1 (en) 2017-02-02
DK2821407T3 (da) 2017-01-02
TWI522355B (zh) 2016-02-21
US20120122911A1 (en) 2012-05-17
PT2638042E (pt) 2014-12-09
US8754096B2 (en) 2014-06-17
ME01922B (me) 2015-05-20
US9833448B2 (en) 2017-12-05
US20120122900A1 (en) 2012-05-17
CN103328478A (zh) 2013-09-25
MA34650B1 (fr) 2013-11-02
US20210008055A1 (en) 2021-01-14
TW201305165A (zh) 2013-02-01
KR20130087037A (ko) 2013-08-05
SI2821407T1 (sl) 2016-12-30
BR112013011448B8 (pt) 2022-03-29
TWI487706B (zh) 2015-06-11
EP2638042B1 (en) 2014-09-24
HK1200163A1 (zh) 2015-07-31
RS55416B1 (sr) 2017-04-28
PE20140240A1 (es) 2014-03-14
JP2013542260A (ja) 2013-11-21
HRP20141108T1 (hr) 2015-01-16
US10272077B2 (en) 2019-04-30
RS53610B1 (en) 2015-04-30
WO2012064910A1 (en) 2012-05-18
US20120122899A1 (en) 2012-05-17
DOP2013000103A (es) 2013-10-15
US20150005330A1 (en) 2015-01-01
SG10201509335VA (en) 2015-12-30
US20180092900A1 (en) 2018-04-05
FR23C1039I1 (fr) 2023-12-08
IL225978A0 (en) 2013-06-27
SG190137A1 (en) 2013-07-31
BR112013011448A2 (pt) 2016-08-09
CA2817100C (en) 2015-09-29
CL2013001289A1 (es) 2013-08-09
CA2817100A1 (en) 2012-05-18
MX2013005246A (es) 2013-05-28

Similar Documents

Publication Publication Date Title
NI201300043A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
ECSP15022555A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
MX342161B (es) Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
CO6351717A2 (es) Tripiridil carboxamida como antagonista del receptor de orexina
GT201200201A (es) Moduladores alostéricos positivos de receptores m1 de la quinolina amida
WO2013169574A3 (en) Aliphatic spirolactam cgrp receptor antagonists
CO6541545A2 (es) Compuestos de espiropiperidina como antagonistas del receptor orl-1
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
EA201490037A1 (ru) Антагонисты trpv4
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
MX2015011536A (es) Nuevos antagonistas de receptores trpa1 de sulfamidas.
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
TN2013000179A1 (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
CL2010000998A1 (es) Compuestos derivados de arilsulfonil pirazolin carboxamidina, antagonistas de 5-ht6; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento o profilaxis de enfermedades tales como psicosis, epilepsia, enfermedad de parkinson, migraña y enfermedad de alzheimer.
UA109463C2 (xx) Піперидинонкарбоксамідазаіндани - антагоністи рецептора cgrp